Similarly, Pillai et al.’s study on NSCLC indicated that the efficacy and toxicity profiles of PD-1 and PDL-1 inhibitors appeared similar, although immune-related adverse events were slightly more frequent in patients receiving PD-1 inhibitors (29). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.